Gene

FGFR1

fibroblast growth factor receptor 1

Explore in graph →CI-GENE-00001922HGNC:3688 ENSG00000077782 NCBI 2260 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (81)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–50 of 81 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FGFR1 Fusion1
Fexagratinib	Carcinoma	Predictive	C	Supports Sensitivity Response	1	submitted	EID9243 Phase II study (NCT02465060) from NCI-MATCH Trial (EAY131) Subprotocol W addressed the use of AZD4547 (an FGFR 1-3 inhibitor) in 48 tumor patients carrying FGFR 1-3 variants. Partial responses were ob…

Cohorts

Alteration frequency by cohort (94)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved94 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Colorectal Cancer (MSK, JCO Precis Oncol 2022) crc_dd_2022	Colorectal Adenocarcinoma	Ssm	5

Literature

Linked publications (42)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 42 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
· Blood · 2016 · PMID 27069254 · validated civic_curation pubmed
Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
· J Natl Cancer Inst · 2021 · PMID 32940689 · validated civic_curation pubmed
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.
· Breast Cancer Res · 2021 · PMID 33579347 · validated civic_curation pubmed
Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.
· J Clin Oncol · 2013 · PMID 23182986

FGFR1 Fusion1
(oncogenic)	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Oncogenic	C	Supports Oncogenicity	2	submitted	EID11726 70 yo with t(8;22)(p11;q11) and BCR::FGFR1 rearrangement presenting as pre-B ALL with complex cytogenetic abnormalities. Flow cytometric analysis at diagnosis showed B cell immunophenotype. BCR-FGFR1 … (full text at CIViC) PMID 20594995 · Baldazzi et al., 2010 · Open in CIViC	civic

FGFR1 Fusion1

(oncogenic)

B Lymphoblastic Leukemia/LymphomaCURATED_BROADER

Oncogenic

Supports Oncogenicity

submitted

EID11726

70 yo with t(8;22)(p11;q11) and BCR::FGFR1 rearrangement presenting as pre-B ALL with complex cytogenetic abnormalities. Flow cytometric analysis at diagnosis showed B cell immunophenotype. BCR-FGFR1 … (full text at CIViC)

PMID 20594995 · Baldazzi et al., 2010 · Open in CIViC

FGFR1 Amplification36
(prognostic)	Malignant Breast Neoplasm	Prognostic	B	Supports Poor Outcome	5	accepted	EID12486 PALOMA-3, a phase III, multicenter, double-blind randomized controlled trial enrolled patients with advanced estrogen receptor-positive breast cancer receiving fulvestrant (estrogen receptor antagonis… (full text at CIViC) PMID 32940689 · O'Leary et al., 2021 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Prognostic	B	Supports Poor Outcome	5	accepted	EID12497 Amplification of FGFR1 is one molecular alteration associated with hormonal resistance and relapse in breast cancer. Using two different patient data cohorts (H12O - patients diagnosed at Hospital 12 … (full text at CIViC) PMID 33579347 · Mouron et al., 2021 · Open in CIViC	civic
〃	Lung Squamous Cell Carcinoma	Prognostic	B	Supports Poor Outcome	4	accepted	EID682 In this study in surgically resected squamous cell lung cancer, FGFR1 amplification has been shown as an independent negative prognostic factor in Asian patients. FGFR1 amplification also correlates w… (full text at CIViC) PMID 23182986 · Kim et al., 2013 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Prognostic	B	Supports Poor Outcome	4	accepted	EID685 Meta-Analysis on prognostic value of FGFR1 amplification in different types of cancer shows significantly worse overall survival for patients with FGFR1 and FGFR2 amplification. However, larger studie… (full text at CIViC) PMID 25171497 · Chang et al., 2014 · Open in CIViC	civic
〃	Lung Squamous Cell Carcinoma	Prognostic	B	Does Not Support Poor Outcome	4	accepted	EID687 Effect of FGFR1 amplification on survival unclear, no significant correlation with PFS and OS seen in this meta-analysis. However, FGFR1 amplification is significantly correlated with lymph node metas… (full text at CIViC) PMID 25433983 · Jiang et al., 2015 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Prognostic	B	Supports Poor Outcome	4	submitted	EID12532 In a cohort of 100 patients with metastatic breast cancer, FGFR1 Amplification was found in 20 cases via FISH, with 17 cases classified as amplified and three cases as low amplified using published cr… (full text at CIViC) PMID 32517171 · Bourrier et al., 2020 · Open in CIViC	civic
〃	Lung Squamous Cell Carcinoma	Prognostic	B	Supports Poor Outcome	3	accepted	EID683 This study shows an association of FGFR1 amplification with shorter overall and disease-free survival. However, no statistically significant association is seen on multivariate analysis. PMID 25086725 · Seo et al., 2014 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Prognostic	B	Supports Poor Outcome	3	accepted	EID12487 This study aimed to determine the amplification rates of FGFR1, FGFR2, and FGFR3 in breast cancer and evaluate their impact on prognosis. In a cohort of 894 breast cancer patients, FGFR1 amplification… (full text at CIViC) PMID 32852708 · Erber et al., 2020 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Prognostic	B	Supports Better Outcome	2	accepted	EID684 This study shows a reduction in the risk of death for patients with FGFR1 copy-number between 4 and 6. No difference in survival is seen between amplified and non-amplified patients in general. PMID 23806793 · Tran et al., 2013 · Open in CIViC	civic
Afimoxifene	Malignant Breast Neoplasm	Predictive	D	Supports Resistance	3	accepted	EID1105 FGFR1-amplified breast cancer cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1. PMID 20179196 · Turner et al., 2010 · Open in CIViC	civic
Dovitinib	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	2	accepted	EID1604 Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study. Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11… (full text at CIViC) PMID 23658459 · André et al., 2013 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	2	accepted	EID3027 Clinical trial studied the efficacy of Dovitinib on 26 patients with FGFR1 amplifications. Objective response for the cohort was 11.5%, disease control rate was 50%. 11.5% of patients exhibited partia… (full text at CIViC) PMID 27315356 · Lim et al., 2016 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	2	accepted	EID12478 Dovitinib, a pan-FGFR small molecular inhibitor, has shown activity in pre-clinical models against FGFR-expressing breast cancer model cell lines, as well as as in a single agent in a phase II clinica… (full text at CIViC) PMID 28183331 · Musolino et al., 2017 · Open in CIViC	civic
Endocrine Drug Therapy + EverolimusCombination	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID12498 In a clinical cohort of patients with HR+/HER2- metastatic breast cancer (n=110), FGFR1 amplification status was determined using FISH analysis (FGFR1/centromere 8 ratio ≥2). Among those receiving end… (full text at CIViC) PMID 31371343 · Drago et al., 2019 · Open in CIViC	civic
Erdafitinib	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	2	accepted	EID12469 Fibroblast Growth Factor Receptor 1 (FGFR1) amplification is frequently observed in estrogen receptor-positive (ER+) breast cancer and is associated with poor prognosis and resistance to endocrine the… (full text at CIViC) PMID 38603651 · Gong et al., 2024 · Open in CIViC	civic
〃	Malignant Lung Neoplasm	Predictive	D	Supports Sensitivity Response	2	submitted	EID7954 JNJ-42756493 (erdafitinib) inhibitory effect was tested across a broad panel of lung cancer cell lines. Increased inhibit was associated with FGFR1 amplification. However, not all FGFR1-amplified ce… (full text at CIViC) PMID 28341788 · Perera et al., 2017 · Open in CIViC	civic
Erdafitinib + Fulvestrant + PalbociclibCombination	Malignant Breast Neoplasm	Predictive	B	Does Not Support Sensitivity Response	1	submitted	EID12485 Hormone-receptor positive HER2-negative (HR+) breast cancers can harbor alterations in fibroblast growth factor receptors (FGFRs), particularly FGFR1 amplification, which is associated with poor progn… (full text at CIViC) PMID 40627530 · Gonzalez-Ericsson et al., 2025 · Open in CIViC	civic
Erdafitinib Regimen	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	2	rejected	EID12468 The NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1 was an open-label, single-arm, phase II study that required central confirmation of FGFR1–4 amplification in tumors. 18 patients were enrolled, i… (full text at CIViC) PMID 39040443 · Marin et al., 2024 · Open in CIViC	civic
Fexagratinib	HER2 Negative Breast CancerUNRESOLVED	Predictive	C	Supports Sensitivity Response	2	accepted	EID1991 Eight patients with advanced HER2-negative breast cancer and FGFR1 amplification were evaluated for response to AZD4547. One patient (12.4%) demonstrated a confirmed response to AZD4547. In a preclini… (full text at CIViC) PMID 27179038 · Pearson et al., 2016 · Open in CIViC	civic
Fulvestrant + LucitanibCombination	Estrogen Receptor-positive Breast CancerUNRESOLVED	Predictive	B	Supports Sensitivity Response	2	submitted	EID12751 In a neoadjuvant letrozole study of ER+/HER2− breast cancer (n = 72), FGFR1 amplification was enriched in endocrine-resistant tumors (9/21, 43%) versus sensitive (3/40, 7%) and intermediate (1/11, 10%… (full text at CIViC) PMID 28751448 · Formisano et al., 2017 · Open in CIViC	civic
Fulvestrant + Palbociclib + RogaratinibCombination	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	5	accepted	EID12503 To determine if there is a causal relationship between hormonal blockade (a frequent treatment for tumors in the adjuvant setting) and FGFR1 amplification/overexpression, this study used two non-FGFR1… (full text at CIViC) PMID 33579347 · Mouron et al., 2021 · Open in CIViC	civic
Futibatinib	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	3	accepted	EID12547 Futibatinib is a selective FGFR inhibitor. In this 2020 preclinical study, its antitumor activity was evaluated in cancer cell lines and xenograft models. The antiproliferative activity was assessed … (full text at CIViC) PMID 32973082 · Sootome et al., 2020 · Open in CIViC	civic
Infigratinib	Lung Squamous Cell Carcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID1908 Phase 1 study of FGFR-inhibitor BGJ398 (infigratinib) in advanced cancer with FGFR-aberrations (n=132). In the subgroup of FGFR1-amplified squamous NSCLC (as classified by FISH), 36 patients were trea… (full text at CIViC) PMID 27870574 · Nogova et al., 2017 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Predictive	B	Does Not Support Resistance	2	accepted	EID1909 Phase 1 study of FGFR-inhibitor BGJ398 (infigratinib) in advanced cancer with FGFR-aberrations (n=132). Among the 21 continuously treated (>100mg) patients with breast cancer and FGFR1 amplification (… (full text at CIViC) PMID 27870574 · Nogova et al., 2017 · Open in CIViC	civic
〃	Bladder Carcinoma	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID1911 Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. Of the eight patients with FGFR3-mutated bladder/urothelial cancer, one patient with FGFR1 amplification was treated wi… (full text at CIViC) PMID 27870574 · Nogova et al., 2017 · Open in CIViC	civic
Lucitanib	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	3	accepted	EID7488 In a phase 1 trial, patients with advanced solid tumors were treated with FGFR1/2, VEGFR1/2/3, and PDGFR inhibitor lucitanib. Among 12 patients with breast cancer harboring FGFR alterations (8 FGFR1 a… (full text at CIViC) PMID 25193991 · Soria et al., 2014 · Open in CIViC	civic
〃	Malignant Breast Neoplasm	Predictive	B	Supports Sensitivity Response	3	submitted	EID12488 HR+/HER2– breast cancers frequently harbor fibroblast growth factor receptor (FGFR) alterations, and FGFR1 amplification has been linked to poor prognosis and resistance to both endocrine therapy and … (full text at CIViC) PMID 31619444 · Hui et al., 2020 · Open in CIViC	civic
Pazopanib	Malignant Breast Neoplasm	Predictive	C	Supports Sensitivity Response	2	accepted	EID7246 Case report in a HR positive, Her2/neu negative breast cancer patient harboring an FGFR1 amplification. The patient responded to treatment to Pazopanib - including a near CR of brain metastases. Durat… (full text at CIViC) PMID 29223982 · Cheng et al., 2017 · Open in CIViC	civic
PD173074	Lung Squamous Cell Carcinoma	Predictive	D	Supports Sensitivity Response	5	accepted	EID680 Preclinical (in-vitro, in-vivo) evidence suggests predictive value of FGFR1 amplification for treatment with FGFR1-inhibitors. 4 of 83 cell lines exhibited FGFR1 amplification, and 3 of these were hig… (full text at CIViC) PMID 21160078 · Weiss et al., 2010 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	4	accepted	EID686 Preclinical study showing FGFR1 amplification in NSCLC and efficacy of FGFR-1 inhibition in one amplified cell line. PMID 21666749 · Dutt et al., 2011 · Open in CIViC	civic
Pemigatinib	Malignant Breast Neoplasm	Predictive	C	Does Not Support Sensitivity Response	3	accepted	EID12542 The phase 2 FIGHT-207 basket study was designed to evaluate pemigatinib, a selective FGFR inhibitor, in patients with previously treated advanced solid tumors harboring FGFR alterations. Eligible pati… (full text at CIViC) PMID 38710951 · Rodón et al., 2024 · Open in CIViC	civic
Ponatinib	Bone Ewing SarcomaALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID1247 116 Ewing's sarcoma tumor samples were analyzed in this study. 2 patient's samples underwent whole genome sequencing, tumor samples from 51 patients underwent exome sequencing and expression analysis,… (full text at CIViC) PMID 26179511 · Agelopoulos et al., 2015 · Open in CIViC	civic
〃	Estrogen Receptor-positive Breast CancerUNRESOLVED	Predictive	D	Supports Sensitivity Response	3	accepted	EID1767 In MDA-MB-134 cells (ER-positive breast cancer cells with amplified FGFR1) ponatinib potently inhibited cell growth with a GI50 value of 23 nmol/L and inhibited FGFR1 phosphorylation with an IC50 valu… (full text at CIViC) PMID 22238366 · Gozgit et al., 2012 · Open in CIViC	civic
Regorafenib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	submitted	EID13263 Among 76 patients with refractory metastatic colorectal cancer treated with regorafenib, FGFR1 amplification was identified in three patients (3.9%), and all three achieved a partial response to regor… (full text at CIViC) PMID 33224274 · Lee et al., 2020 · Open in CIViC	civic
Lucitanib + RogaratinibSubstitutes	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	2	accepted	EID12505 FGFR1 amplification (FGFR1amp) is frequently detected in metastatic breast cancer (MBC), where it is recognized as a generic marker of poor prognosis and most notably, resistance to CDK4/6 inhibitors … (full text at CIViC) PMID 34593528 · Sánchez-Guixé et al., 2022 · Open in CIViC	civic
Sunitinib	Malignant Breast Neoplasm	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID12479 The Targeted Agent and Profiling Utilizing Registry (TAPUR) study is a prospective, phase II, basket trial that aims to evaluate the antitumor activity of commercially available targeted therapies pre… (full text at CIViC) PMID 38354330 · Calfa et al., 2024 · Open in CIViC	civic